Q2 Earnings Forecast for Compugen Issued By Leerink Partnrs

Compugen Ltd. (NASDAQ:CGEN - Free Report) - Research analysts at Leerink Partnrs issued their Q2 2025 earnings per share estimates for shares of Compugen in a report released on Monday, May 19th. Leerink Partnrs analyst D. Graybosch anticipates that the biotechnology company will post earnings of ($0.11) per share for the quarter. The consensus estimate for Compugen's current full-year earnings is ($0.03) per share. Leerink Partnrs also issued estimates for Compugen's Q3 2025 earnings at ($0.11) EPS, Q1 2026 earnings at ($0.11) EPS, Q2 2026 earnings at ($0.11) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.11) EPS and FY2029 earnings at ($0.19) EPS.

Separately, Wall Street Zen downgraded Compugen from a "buy" rating to a "hold" rating in a research note on Wednesday, March 5th.

Compugen Stock Down 1.4%

NASDAQ CGEN traded down $0.02 during trading hours on Wednesday, hitting $1.45. 173,553 shares of the company were exchanged, compared to its average volume of 370,607. The firm has a market cap of $129.39 million, a price-to-earnings ratio of 72.50 and a beta of 2.61. The company has a 50 day moving average of $1.41 and a two-hundred day moving average of $1.68. Compugen has a 52-week low of $1.13 and a 52-week high of $2.66.

Compugen (NASDAQ:CGEN - Get Free Report) last announced its earnings results on Monday, May 19th. The biotechnology company reported ($0.08) EPS for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.02). Compugen had a net margin of 2.67% and a return on equity of 2.62%. The firm had revenue of $2.28 million for the quarter, compared to analysts' expectations of $3.70 million. During the same quarter last year, the business earned ($0.08) earnings per share.

Institutional Investors Weigh In On Compugen

A number of institutional investors have recently modified their holdings of CGEN. US Bancorp DE bought a new stake in Compugen in the first quarter valued at $29,000. Commonwealth Equity Services LLC acquired a new stake in Compugen during the fourth quarter valued at approximately $32,000. Calamos Wealth Management LLC bought a new position in shares of Compugen in the first quarter valued at $43,000. Two Sigma Advisers LP lifted its holdings in shares of Compugen by 93.6% during the fourth quarter. Two Sigma Advisers LP now owns 35,784 shares of the biotechnology company's stock valued at $55,000 after purchasing an additional 17,300 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Compugen during the 4th quarter worth about $81,000. Institutional investors and hedge funds own 12.22% of the company's stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.